Keck Medicine of USC physicians are enrolling patients as part of an international clinical trial, designed to assess the safety and efficacy of the antiviral drug DAS181, as a possible treatment for patients with severe COVID-19.

Cell biologists have developed a method for SARS-CoV-2 testing that delivers results around ten times faster than current tests.

Researchers have discovered that the presence of circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs) in the plasma of women's blood are critical indicators for the prediction of disease recurrence and disease-free survival.

Strains of a common subtype of influenza virus, H3N2, have almost universally acquired a mutation that effectively blocks antibodies from binding to a key viral protein.

A recent preprint study published in medRxiv, indicates that there is a rapid decline in the levels of SARS-CoV-2 neutralizing antibodies during the weeks following initial infection.

After only a few days caring for critically ill COVID-19 patients at the start of the outbreak in New York City, Aakriti Gupta, MD, realized that this was much more than a respiratory disease.

Now, a collaborative team have created a novel microbiome-based diagnostic tool that, with the accuracy of the best physicians, quickly and inexpensively identifies liver fibrosis and cirrhosis over 90 percent of the time in human patients.

COVID-19 screening can soon be conducted directly at various testing stations, and patients can get their test results in about an hour from the time they get a nasal swab.

How the mass spectrometry works in biopharmaceutical development?

Changes in blood platelets triggered by COVID-19 could contribute to the onset of heart attacks, strokes, and other serious complications in some patients who have the disease, according to University of Utah Health scientists.

The Rogers group and researchers at Shirley Ryan AbilityLab introduced a novel wearable device and set of data algorithms specifically tailored to catch early signs and symptoms associated with COVID-19 and to monitor patients as the illness progresses.

The Danaher Corp. company received emergency use authorization for its Access SARS-CoV-2 IgG test.

Sera Prognostics is developing a biomarker test for?predicting very preterm birth.

New research will help health-care practitioners to more accurately diagnose disease and illness in newborn babies from urine samples, according to a study by researchers at the University of Alberta and the Universidad Autónoma de Zacatecas.

The American Red Cross has begun testing all blood, platelet and plasma donations for COVID-19 antibodies.